within Pharmacolibrary.Drugs.ATC.L;

model L01DC02
  extends Pharmacokinetic.Models.PK_2C(
    weight         = 70,
    F              = 1,
    Cl             = 0.00075,
    adminDuration  = 600,
    adminMass      = 25 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.015,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,            
    Vdp             = 0.07,
    k12             = 30,
    k21             = 30
    
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>L01DC02</td></tr><td>route:</td><td>intravenous</td></tr><tr><td>n-compartments</td><td>2</td></tr></table><p>Plicamycin, also known as mithramycin, is an antineoplastic antibiotic that was formerly used in the treatment of testicular cancer and hypercalcemia associated with cancer. Due to significant toxicity, especially hepatotoxicity and bleeding events, plicamycin is no longer in general clinical use and is not approved for use today.</p><h4>Pharmacokinetics</h4><p>Estimated typical adult parameters; published human pharmacokinetic data for plicamycin are scarce or unavailable. Parameters are based on secondary pharmacology references and chemical analogies.</p><h4>References</h4><ol><li><p>Coukell, AJ, &amp; Markham, A (1998). Pamidronate. A review of its use in the management of osteolytic bone metastases, tumour-induced hypercalcaemia and Paget&#x27;s disease of bone. <i>Drugs &amp; aging</i> 12(2) 149–168. DOI:<a href=\"https://doi.org/10.2165/00002512-199812020-00007\">10.2165/00002512-199812020-00007</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/9509293/\">https://pubmed.ncbi.nlm.nih.gov/9509293</a></p></li><li><p>Fang, K, et al., &amp; Ho, DH (1992). Determination of plicamycin in plasma by radioimmunoassay. <i>Therapeutic drug monitoring</i> 14(3) 255–260. DOI:<a href=\"https://doi.org/10.1097/00007691-199206000-00013\">10.1097/00007691-199206000-00013</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/1412612/\">https://pubmed.ncbi.nlm.nih.gov/1412612</a></p></li><li><p>Singer, FR, &amp; Fernandez, M (1987). Therapy of hypercalcemia of malignancy. <i>The American journal of medicine</i> 82(2A) 34–41. DOI:<a href=\"https://doi.org/10.1016/0002-9343(87)90485-2\">10.1016/0002-9343(87)90485-2</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/3826096/\">https://pubmed.ncbi.nlm.nih.gov/3826096</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end L01DC02;
